1. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, June 1999, Draft Guidance for Industry, Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action. (Superseded by April 2003 Draft Guidance with same name.) [cited 6/20/2011]. Available from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070111.pdf .
2. USP 35/NF 30. Rockville: United States Pharmacopeial Convention, Inc.; 2012. <601>, Aerosols, Nasal Sprays, Metered-Dose Inhalers, and Dry Powder Inhalers; p. 232−52.
3. Newman SP, Steed KP, Hooper G, Brickwell J. Scintigraphic assessment of the oropharyngeal and nasal depositions of fusafungine from a pressurized inhaler and from a novel pump spray device. J Pharm Pharmacol. 1995;47:818–21.
4. Yu CD, Jones RE, Henesian M. Cascade impactor method for the droplet size characterization of a metered-dose nasal spray. J Pharm Sci. 1984;73:344–8.
5. Task Group on Lung Dynamics. Deposition and retention models for internal dosimetry of the human respiratory tract. Health Phys. 1966;12:173–207.